JP2013513596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513596A5 JP2013513596A5 JP2012542622A JP2012542622A JP2013513596A5 JP 2013513596 A5 JP2013513596 A5 JP 2013513596A5 JP 2012542622 A JP2012542622 A JP 2012542622A JP 2012542622 A JP2012542622 A JP 2012542622A JP 2013513596 A5 JP2013513596 A5 JP 2013513596A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- hck
- activity
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 13
- 241000712461 unidentified influenza virus Species 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims 2
- 108010046934 Proto-Oncogene Proteins c-hck Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000013000 chemical inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229950004244 laninamivir Drugs 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- 229960003752 oseltamivir Drugs 0.000 claims 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 2
- 229960001084 peramivir Drugs 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 229960001028 zanamivir Drugs 0.000 claims 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims 1
- -1 4- (4- (3- (3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl) ureido) naphthalen-1-yloxy) pyridin-2-yl Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AVUUHIYJPTWYNX-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 AVUUHIYJPTWYNX-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0921730.8A GB0921730D0 (en) | 2009-12-11 | 2009-12-11 | Method of treatment |
| GB0921730.8 | 2009-12-11 | ||
| PCT/GB2010/052067 WO2011070369A1 (en) | 2009-12-11 | 2010-12-10 | Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016017330A Division JP6247709B2 (ja) | 2009-12-11 | 2016-02-01 | 造血細胞キナーゼ（ｐ５９−ＨＣＫ）の阻害剤およびインフルエンザ感染の処置におけるそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013513596A JP2013513596A (ja) | 2013-04-22 |
| JP2013513596A5 true JP2013513596A5 (enExample) | 2014-01-23 |
Family
ID=41666982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542622A Pending JP2013513596A (ja) | 2009-12-11 | 2010-12-10 | 造血細胞キナーゼ（ｐ５９−ＨＣＫ）の阻害剤およびインフルエンザ感染の処置におけるそれらの使用 |
| JP2016017330A Active JP6247709B2 (ja) | 2009-12-11 | 2016-02-01 | 造血細胞キナーゼ（ｐ５９−ＨＣＫ）の阻害剤およびインフルエンザ感染の処置におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016017330A Active JP6247709B2 (ja) | 2009-12-11 | 2016-02-01 | 造血細胞キナーゼ（ｐ５９−ＨＣＫ）の阻害剤およびインフルエンザ感染の処置におけるそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120244120A1 (enExample) |
| EP (1) | EP2509595B1 (enExample) |
| JP (2) | JP2013513596A (enExample) |
| CN (1) | CN102762204B (enExample) |
| AU (1) | AU2010329645B2 (enExample) |
| GB (1) | GB0921730D0 (enExample) |
| WO (1) | WO2011070369A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA105763C2 (uk) | 2007-12-19 | 2014-06-25 | Кансер Рісерч Текнолоджі Лімітед | 8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011092469A1 (en) | 2010-02-01 | 2011-08-04 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| SG11201400226UA (en) | 2011-10-03 | 2014-09-26 | Respivert Ltd | 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| KR102283876B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제로서 유용한 우레아 유도체 |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3083604A1 (en) | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| CN110522731B (zh) | 2014-02-14 | 2022-08-02 | 瑞斯比维特有限公司 | 作为抗炎化合物的芳族杂环化合物 |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| AU2017245888B2 (en) | 2016-04-06 | 2021-05-13 | Oxular Acquisitions Limited | Kinase inhibitors |
| KR20220038696A (ko) | 2019-07-19 | 2022-03-29 | 아나제네시스 바이오테크놀로지스 에스.에이.에스. | 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
| CN115181736B (zh) * | 2022-01-07 | 2023-05-30 | 中国科学院海洋研究所 | 一种可以结合脂多糖的蛋白酶pck及其制备和应用 |
| US20240365913A1 (en) * | 2023-05-05 | 2024-11-07 | Wilcox Industries Corp. | Reclining helmet mount apparatus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| US7067266B2 (en) * | 2002-07-10 | 2006-06-27 | Rigel Pharmaceuticals, Inc. | Modulators of leukocyte activation, Hck compositions and methods of use |
| AU2006260970B2 (en) | 2005-06-20 | 2012-07-05 | Janssen Sciences Ireland Uc | Heterocyclylaminoalkyl substituted benzimidazoles |
| KR20080076968A (ko) * | 2005-11-23 | 2008-08-20 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하는 방법 |
| ES2378704T3 (es) | 2006-01-27 | 2012-04-17 | Array Biopharma, Inc. | Activadores de la glucocinasa |
| KR20080081359A (ko) | 2006-01-30 | 2008-09-09 | 아이알엠 엘엘씨 | Ｐｐａｒ 조절제로서의 스피로 이미다졸 유도체 |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| WO2008157518A1 (en) * | 2007-06-15 | 2008-12-24 | Drake Richard R | Biomarkers of influenza vaccine response |
| JP2012504591A (ja) * | 2008-10-02 | 2012-02-23 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| JP2012511563A (ja) * | 2008-12-11 | 2012-05-24 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
-
2009
- 2009-12-11 GB GBGB0921730.8A patent/GB0921730D0/en not_active Ceased
-
2010
- 2010-12-10 CN CN201080063651.5A patent/CN102762204B/zh active Active
- 2010-12-10 EP EP10788125.2A patent/EP2509595B1/en active Active
- 2010-12-10 US US13/514,644 patent/US20120244120A1/en not_active Abandoned
- 2010-12-10 WO PCT/GB2010/052067 patent/WO2011070369A1/en not_active Ceased
- 2010-12-10 AU AU2010329645A patent/AU2010329645B2/en active Active
- 2010-12-10 JP JP2012542622A patent/JP2013513596A/ja active Pending
-
2015
- 2015-10-14 US US14/883,464 patent/US20160045512A1/en not_active Abandoned
-
2016
- 2016-02-01 JP JP2016017330A patent/JP6247709B2/ja active Active
-
2017
- 2017-09-15 US US15/706,152 patent/US20180000830A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513596A5 (enExample) | ||
| JP2013530964A5 (enExample) | ||
| US11629125B2 (en) | Elimination of hepatitis b virus with antiviral agents | |
| AU2014233520B2 (en) | Modulators of the eIF2alpha pathway | |
| KR101799739B1 (ko) | 아폽토시스 신호-조절 키나제 억제제 | |
| EP3021841B1 (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| KR20220026538A (ko) | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 | |
| US10758522B2 (en) | Small molecule analogs of the nemo binding peptide | |
| BR112021000938A2 (pt) | composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto | |
| US20180016243A1 (en) | Human helicase ddx3 inhibitors as therapeutic agents | |
| WO2017037041A1 (en) | Use of indole compounds to stimulate the immune system | |
| US11123340B2 (en) | Small-molecule UT-A-selective urea transport inhibitors | |
| WO2009119167A1 (ja) | 抗ｒｎａウイルス作用を有するアニリン誘導体 | |
| CN104093408A (zh) | 用于治疗纤维化疾病的pi3k抑制剂 | |
| EP4320106A1 (en) | Arylacetyl inhibitors of tg2 and uses thereof | |
| JP2023550053A (ja) | Ｉｒｅ１アルファ阻害剤及びその使用 | |
| JP4793830B2 (ja) | Ｓａｒｓコロナウイルスのｒｎａシュードノット構造に結合してリボソームフレームシフトを抑制するホモピペラジン系化合物 | |
| JP2012519668A5 (enExample) | ||
| KR20090032372A (ko) | 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제 | |
| WO2025037206A1 (en) | Deuterated antiviral compounds | |
| WO2023114759A2 (en) | Abl inhibitors and uses thereof | |
| JP2005232101A (ja) | セレコキシブアミノアルキル誘導体 | |
| CA3066706A1 (en) | Modulators of indoleamine 2,3-dioxygenase | |
| EA041357B1 (ru) | Противовирусные соединения для элиминации вируса гепатита b | |
| HK1224180B (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |